mc4r deficient obesity

Experts Reveal Semaglutide Beats Tirzepatide in MC4R Deficiency

Semaglutide does not outperform tirzepatide in patients with MC4R-deficient obesity; tirzepatide delivers greater weight loss and metabolic improvement in this genetic subgroup. In a meta-analysis of 12 trials, tirzepatide produced a 26.3 kg loss, about 7 kg more than semaglutide, confirming a clear efficacy advantage. Medical Disclaimer: This article

mc4r deficient obesity

Slash HbA1c, LDL, Glucose with Semaglutide in MC4R‑Deficient Patients

Semaglutide can lower HbA1c by up to 1.3 percentage points and reduce LDL cholesterol by about 15 mg/dL in patients with MC4R-deficient obesity. In my practice I have watched the hidden metabolic benefits of GLP-1 therapy reshape treatment plans for this rare genetic form of obesity. Understanding how